Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind active-controlled trial of baricitinib in DMARD-naive or minimally treated rheumatoid arthritis
KCT0000998Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2013
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in rheumatoid arthritis (RA), sponsored by Eli Lilly and Company. Started May 2013; status: recruiting.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on KCT0000998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000998.